Avalo Therapeutics (AVTX) Retained Earnings (2014 - 2026)

Avalo Therapeutics has reported Retained Earnings for 13 years, with the latest figure at -$468.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 22.1% year-over-year to -$468.2 million; the trailing twelve-month figure through Mar 2026 stood at -$468.2 million (down 22.1% YoY), and the FY2025 full-year result was -$448.5 million, changed N/A from the prior year.
• Retained Earnings for Q1 2026 stood at -$468.2 million, down from -$448.5 million in the prior quarter.
• The five-year high for Retained Earnings was -$34000.0 in Q2 2025, with the low at -$468.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$335.1 million across 5 years, with a median of -$330.9 million in 2023.
• Annual changes were most pronounced in 2024 — Retained Earnings plunged 45.45% — and 2025, when it surged 99.99%.
• Avalo Therapeutics' Retained Earnings stood at -$303.8 million in 2022, then fell by 10.31% to -$335.1 million in 2023, then advanced by 0.06% to -$334.9 million in 2024, then sank by 33.92% to -$448.5 million in 2025, then declined by 4.38% to -$468.2 million in 2026.
• The last three Retained Earnings figures came in at -$468.2 million (Q1 2026), -$448.5 million (Q4 2025), and -$434.8 million (Q3 2025), per Business Quant data.